The estimated Net Worth of Lawrence S Lewin is at least $43.8 Тысяча dollars as of 20 September 2006. Lawrence Lewin owns over 973 units of abrdn Life Sciences Investors stock worth over $43,800 and over the last 20 years Lawrence sold HQL stock worth over $0.
Lawrence has made over 2 trades of the abrdn Life Sciences Investors stock since 2004, according to the Form 4 filled with the SEC. Most recently Lawrence bought 973 units of HQL stock worth $12,474 on 20 September 2006.
The largest trade Lawrence's ever made was buying 1,488 units of abrdn Life Sciences Investors stock on 25 June 2004 worth over $24,998. On average, Lawrence trades about 1,231 units every 409 days since 2004. As of 20 September 2006 Lawrence still owns at least 2,920 units of abrdn Life Sciences Investors stock.
You can see the complete history of Lawrence Lewin stock trades at the bottom of the page.
Lawrence's mailing address filed with the SEC is C/O HAMBRECHT & QUIST CAPITAL MANAGEMENT, 30 ROWES WHARF, 4TH FLOOR, BOSTON, MA, 02110-3328.
Over the last 20 years, insiders at abrdn Life Sciences Investors have traded over $26,240 worth of abrdn Life Sciences Investors stock and bought 920,961 units worth $12,356,710 . The most active insiders traders include Capital Management, L.P.Wei..., Daniel R Omstead и Jeffrey Allen Bailey. On average, abrdn Life Sciences Investors executives and independent directors trade stock every 129 days with the average trade being worth of $242,880. The most recent stock trade was executed by Bill Maher on 23 August 2024, trading 650 units of HQL stock currently worth $9,991.
tekla life sciences investors is a closed-ended equity mutual fund launched and managed by tekla capital management llc. the fund invests in public equity markets across the globe. it seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. the fund primarily invests in growth stocks of small cap companies. it employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. the fund benchmarks the performance of its portfolio against the nasdaq biotech index and the s&p 500 index. it was form
abrdn Life Sciences Investors executives and other stock owners filed with the SEC include: